Der Anaesthesist
-
Randomized Controlled Trial Clinical Trial
[Hemodynamic effects of the new phosphodiesterase inhibitor enoximone in heart surgery patients].
The new phosphodiesterase-III inhibitor (PDI) enoximone is a non-catecholamine, non-glycoside cardiotonic agent with concomitant vasodilating properties. It has proved beneficial in patients with severe chronic heart failure. The influence of enoximone i.v. on hemodynamics was investigated during cardiac surgery under various conditions. ⋯ CONCLUSION. Arterial and venous vasodilation with an increase in myocardial performance (dp/dtmax) resulting in an increase in CI were the predominant hemodynamic effects of enoximone i.v. No arrhythmogenic effects or interactions with the anesthetics used were observed in this study.
-
Randomized Controlled Trial Clinical Trial
[Interactions of H2 antagonists and non-depolarizing muscle relaxants].
Many drugs potentiate the action of non depolarizing relaxants. These interactions are of clinical importance if such drugs are administered during the perioperative period. H2 Antagonists are increasingly often used for premedication. ⋯ Experimental investigation has shown that calcium reverses the cimetidine effects. It is therefore probable that the cimetidine--relaxant interaction occurs at the presynaptic level. Careful observation seems to be necessary if H2 antagonists, especially cimetidine, are administered intraoperatively at the same time as drugs that also enhance
-
Case Reports
[Complications caused by a Swan-Ganz catheter. An inadvertent entrapment in the right atrium during cardiac surgery].
Insertion of a Swan-Ganz catheter for measurement of pulmonary artery and pulmonary capillary wedge pressures is common for operative management of patients with borderline left ventricular function. However, use of the catheter has associated risks. This case report illustrates the inadvertent snaring, by a suture, of a Swan-Ganz line in the right atrium and its subsequent removal transvenously during rethoracotomy.